T1	DISO 810 813	CCR
#1	AnnotatorNotes T1	C0007134; Renal Cell Carcinoma; Neoplastic Process
T2	PROC 57 70	inmunoterapia
#2	AnnotatorNotes T2	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
T3	CHEM 103 113	ipilimumab
#3	AnnotatorNotes T3	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 123 132	nivolumab
#4	AnnotatorNotes T4	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 136 147	monoterapia
#5	AnnotatorNotes T5	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T6	DISO 165 180	cáncer de riñón
#6	AnnotatorNotes T6	C0740457; Malignant neoplasm of kidney; Neoplastic Process
T7	PROC 212 254	Estudio fase 3b, aleatorizado, doble ciego
T8	CHEM 259 268	nivolumab
#7	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 288 298	ipilimumab
#8	AnnotatorNotes T9	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 308 317	nivolumab
#9	AnnotatorNotes T10	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	PROC 321 332	monoterapia
#10	AnnotatorNotes T11	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T12	DISO 350 378	carcinoma de células renales
#11	AnnotatorNotes T12	C0007134; Renal Cell Carcinoma; Neoplastic Process
T13	DISO 921 925	CCRm
T14	PROC 392 399	tratado
#12	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	DISO 478 506	Carcinoma de células renales
#13	AnnotatorNotes T15	C0007134; Renal Cell Carcinoma; Neoplastic Process
T16	DISO 533 561	Carcinoma de células renales
#14	AnnotatorNotes T16	C0007134; Renal Cell Carcinoma; Neoplastic Process
T17	CHEM 1452 1462	anti-CD137
T18	DISO 668 716	carcinoma renal con componente de células claras
T19	ANAT 702 716	células claras
T20	DISO 780 808	Carcinoma de células renales
#16	AnnotatorNotes T20	C0007134; Renal Cell Carcinoma; Neoplastic Process
T21	PROC 843 850	cirugía
#17	AnnotatorNotes T21	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T22	PROC 853 865	radioterapia
#18	AnnotatorNotes T22	C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T23	DISO 879 919	carcinoma de células renales metastásico
#19	AnnotatorNotes T23	C4721698; Metastatic Renal Cell Carcinoma; Neoplastic Process
T24	DISO 931 949	Enfermedad medible
#20	AnnotatorNotes T24	C1513041; Measurable Disease; Disease or Syndrome
T25	PROC 959 983	tomografía computarizada
#21	AnnotatorNotes T25	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T26	PROC 991 1011	resonancia magnética
#22	AnnotatorNotes T26	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T27	PROC 1013 1015	RM
#23	AnnotatorNotes T27	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T28	PROC 1076 1097	tratamiento sistémico
T29	DISO 1110 1113	CCR
#24	AnnotatorNotes T29	C0007134; Renal Cell Carcinoma; Neoplastic Process
T30	ANAT 1321 1324	SNC
#25	AnnotatorNotes T30	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T31	DISO 1336 1357	Enfermedad autoinmune
#26	AnnotatorNotes T31	C0004364; Autoimmune Diseases; Disease or Syndrome
T32	PROC 1391 1402	Tratamiento
#27	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	CHEM 1417 1426	anti-PD-1
T34	CHEM 1428 1438	anti-PD-L1
T35	CHEM 1464 1486	anticuerpo anti CTLA-4
T36	CHEM 1505 1603	agente que se dirige específicamente a la co-estimulación de las células T o a las vías de control
#28	AnnotatorNotes T36	C3192215; Selective T Cell Costimulation Blocker; Pharmacologic Substance (?) | C4684977; Immune Checkpoint Inhibitors; Pharmacologic Substance (?)
T37	ANAT 1570 1579	células T
#29	AnnotatorNotes T37	C0039194; T-Lymphocyte; Cell
T38	CHEM 1440 1450	anti-PD-L2
T39	CHEM 74 83	nivolumab
#30	AnnotatorNotes T39	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	ANAT 175 180	riñón
#31	AnnotatorNotes T40	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T41	ANAT 363 378	células renales
T42	ANAT 491 506	células renales
T43	ANAT 546 561	células renales
T44	ANAT 678 683	renal
#32	AnnotatorNotes T44	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T45	ANAT 793 808	células renales
T46	ANAT 892 907	células renales
T47	PROC 985 987	TC
#33	AnnotatorNotes T47	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T48	DISO 1280 1319	metástasis del sistema nervioso central
T49	ANAT 1295 1319	sistema nervioso central
#34	AnnotatorNotes T49	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T50	Date 13 17	2018
T51	LIVB 151 160	pacientes
#35	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T52	LIVB 336 345	pacientes
#36	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	Neg_cue 389 391	no
T54	LIVB 728 737	pacientes
#37	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T56	Neg_cue 825 842	no susceptible de
T59	Neg_cue 1069 1075	ningún
T60	Spec_cue 1377 1387	sospechosa
T55	LIVB 1122 1135	participantes
#38	AnnotatorNotes T55	C4554048; Study Participant; Population Group
T57	PHYS 1547 1579	co-estimulación de las células T
#39	AnnotatorNotes T57	C1622572; T cell costimulation; Cell Function
T58	PROC 640 664	Confirmación histológica
#40	AnnotatorNotes T58	C0344441; Histology Procedure; Laboratory Procedure
T61	Observation 755 775	rasgos sarcomatoides
#41	AnnotatorNotes T61	C1519183; Sarcomatoid Features; Finding
A1	Assertion T14 Negated
A2	Assertion T21 Negated
A3	Assertion T22 Negated
A4	Assertion T28 Negated
A5	Assertion T31 Speculated
A6	Status T14 History_of
A7	Status T28 History_of
A8	Status T32 History_of
A9	Status T33 History_of
A10	Status T34 History_of
A11	Status T38 History_of
A12	Status T17 History_of
A13	Status T35 History_of
A14	Status T36 History_of
A15	Status T31 History_of
#42	AnnotatorNotes T7	C1706097; Trial Phase 3B; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#43	AnnotatorNotes T13	C4721698; Metastatic Renal Cell Carcinoma; Neoplastic Process
#44	AnnotatorNotes T48	C0686377; CNS metastases; Neoplastic Process
R1	Used_for Arg1:T39 Arg2:T2	
R2	Combined_with Arg1:T39 Arg2:T3	
R3	Used_for Arg1:T4 Arg2:T5	
R4	Experiences Arg1:T51 Arg2:T4	
R5	Experiences Arg1:T51 Arg2:T2	
R6	Experiences Arg1:T51 Arg2:T6	
R7	Location_of Arg1:T40 Arg2:T6	
T62	Quantifier_or_Qualifier 181 189	avanzado
R8	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T62	
R9	Used_for Arg1:T10 Arg2:T11	
R10	Combined_with Arg1:T8 Arg2:T9	
R11	Experiences Arg1:T52 Arg2:T8	
R12	Experiences Arg1:T52 Arg2:T10	
R13	Experiences Arg1:T52 Arg2:T12	
R14	Location_of Arg1:T41 Arg2:T12	
T63	Quantifier_or_Qualifier 379 387	avanzado
R15	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T63	
R16	Negation Arg1:T53 Arg2:T14	
T64	Observation 418 436	factores de riesgo
#45	AnnotatorNotes T64	C0035648; risk factors; Finding
R17	Experiences Arg1:T52 Arg2:T14	
R18	Experiences Arg1:T52 Arg2:T64	
T65	Quantifier_or_Qualifier 437 454	intermedio o alto
R19	Has_Quantifier_or_Qualifier Arg1:T64 Arg2:T65	
R22	Location_of Arg1:T42 Arg2:T15	
R23	Location_of Arg1:T43 Arg2:T16	
T66	Quantifier_or_Qualifier 562 570	avanzado
R24	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T66	
T67	Observation 575 593	factores de riesgo
#46	AnnotatorNotes T67	C0035648; risk factors; Finding
T68	Quantifier_or_Qualifier 594 611	intermedio o alto
R25	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T68	
R26	Overlap Arg1:T12 Arg2:T64	
R27	Overlap Arg1:T16 Arg2:T67	
R28	Location_of Arg1:T45 Arg2:T20	
R29	Location_of Arg1:T44 Arg2:T18	
R30	Experiences Arg1:T54 Arg2:T58	
R31	Experiences Arg1:T54 Arg2:T61	
R32	Experiences Arg1:T54 Arg2:T18	
R33	Location_of Arg1:T45 Arg2:T1	
T69	Quantifier_or_Qualifier 815 823	avanzado
R34	Has_Quantifier_or_Qualifier Arg1:T1 Arg2:T69	
R35	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T69	
R36	Negation Arg1:T56 Arg2:T21	
R37	Negation Arg1:T56 Arg2:T22	
R38	Location_of Arg1:T46 Arg2:T23	
T70	CONC 1037 1047	RECIST 1.1
#47	AnnotatorNotes T70	C4086827; Response Evaluation Criteria in Solid Tumors Version 1.1; Intellectual Product
R40	Negation Arg1:T59 Arg2:T28	
T71	Observation 1151 1175	riesgo intermedio o alto
#48	AnnotatorNotes T71	C4319571; High risk; Finding + C3640764; Intermediate Risk; Finding
R41	Experiences Arg1:T55 Arg2:T71	
T73	CONC 1185 1189	IMDC
#49	AnnotatorNotes T73	C4744412; International Metastatic Renal Cell Carcinoma Database Consortium Criteria; Intellectual Product
T74	CONC 1191 1239	International Metastatic RCC Database Consortium
#50	AnnotatorNotes T74	C4744412; International Metastatic Renal Cell Carcinoma Database Consortium Criteria; Intellectual Product
R43	Location_of Arg1:T49 Arg2:T48	
R44	Location_of Arg1:T30 Arg2:T48	
R45	Speculation Arg1:T60 Arg2:T31	
R46	Used_for Arg1:T33 Arg2:T32	
R47	Used_for Arg1:T34 Arg2:T32	
R48	Used_for Arg1:T38 Arg2:T32	
R49	Used_for Arg1:T35 Arg2:T32	
R50	Used_for Arg1:T36 Arg2:T32	
R51	Location_of Arg1:T37 Arg2:T57	
A16	Assertion T61 Speculated
T75	Spec_cue 742 748	puedan
R20	Speculation Arg1:T75 Arg2:T61	
R21	Location_of Arg1:T46 Arg2:T13	
T76	Quantifier_or_Qualifier 1326 1332	activa
R39	Has_Quantifier_or_Qualifier Arg1:T48 Arg2:T76	
T77	Quantifier_or_Qualifier 1358 1364	activa
R52	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T77	
R53	Overlap Arg1:T18 Arg2:T61	
R54	Used_for Arg1:T4 Arg2:T2	
R42	Location_of Arg1:T19 Arg2:T18	
T72	Quantifier_or_Qualifier 866 875	curativas
R57	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T72	
R58	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T72	
#51	AnnotatorNotes T33	C4289970; Anti-PD1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#52	AnnotatorNotes T34	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#53	AnnotatorNotes T17	C4732974; Anti-CD137 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#54	AnnotatorNotes T28	C1515119; Systemic Therapy; Therapeutic or Preventive Procedure
#15	AnnotatorNotes T62	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
#55	AnnotatorNotes T63	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
#56	AnnotatorNotes T66	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
#57	AnnotatorNotes T69	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
#58	AnnotatorNotes T18	C0279702; Conventional (Clear Cell) Renal Cell Carcinoma; Neoplastic Process (?)
#59	AnnotatorNotes T19	C1513940; Neoplastic Clear Cell; Cell (?)
#60	AnnotatorNotes T77	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
#61	AnnotatorNotes T76	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
T78	Route 1088 1097	sistémico
R55	Has_Route_or_Mode Arg1:T28 Arg2:T78	
#62	AnnotatorNotes T78	C0205373; Systemic; Functional Concept
#63	AnnotatorNotes T35	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
#64	AnnotatorNotes T72	C1880198; Cure (remedy); Conceptual Entity
A17	Experiencer T51 Patient
A18	Experiencer T52 Patient
A19	Experiencer T54 Patient
A20	Experiencer T55 Patient
